SCYNEXIS (SCYX) Insider Tinmouth Brian Philippe Buys 2,875 Shares
Tinmouth Brian Philippe added 2,875 shares to his SCYX holdings on June 26, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Tinmouth Brian Philippe bought 2,875 shares of SCYNEXIS, Inc. ($SCYX) on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SCYX is up 22.9% after 1 week, down 7.3% after 1 month and down 4.7% to date (from the $3.85 close on Jun 26, 2026).
SCYX
SCYNEXIS, Inc.
Key Points
- Tinmouth Brian Philippe bought 2,875 shares of SCYX on June 26, 2026, with shares trading at $4.07 on Wednesday.
- Several institutional investors, including Squadron Capital Management and Vanguard Capital Management, opened new positions in SCYX.
- Analysts from Guggenheim and Ladenburg Thalmann maintain a 'buy' rating on SCYX, with price targets ranging from $3.00 to $15.00.
Get $SCYX trade alerts by text
We text you when insiders, Congress or big funds trade $SCYX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SCYNEXIS, Inc. alert may contain errors. Disclosures
Tinmouth Brian Philippe recently purchased 2,875 shares of SCYX on June 26, 2026. This insider transaction comes as the stock traded at $4.07 on Wednesday.
Other Institutional Activity in SCYX
Several institutional investors have shown interest in SCYX. Squadron Capital Management LLC opened a new position with 7,608,695 shares valued at approximately $6,976,412. Heights Capital Management, Inc followed suit, acquiring 2,086,960 shares worth about $1,913,534. Meanwhile, Avidity Partners Management LP held steady with 2,081,660 shares, showing no change in their position. Kingdon Capital Management, L.L.C. also initiated a new stake with 1,982,491 shares valued at $1,817,746. Additionally, Empery Asset Management, LP and Vanguard Capital Management LLC each opened new positions, holding 1,847,826 and 1,564,398 shares, respectively.
SCYNEXIS, Inc. Stock Down 8.7%
Shares of SCYX traded near $4.07 on Wednesday. The company, known for its work in developing anti-infective therapies, has attracted attention from both insiders and institutional investors alike.
Insider Buying and Selling at SCYNEXIS, Inc.
On June 26, 2026, several insiders, including Armando Anido, Ann Hanham, and David Hastings, each purchased 2,875 shares of SCYX. These transactions were not part of a pre-planned trading program, indicating personal investment decisions.
Analysts Set New Price Targets
Analysts continue to show confidence in SCYX. On October 28, 2025, Guggenheim maintained its 'buy' rating with a price target of $3.00. Ladenburg Thalmann & Co. also reiterated its 'buy' stance, setting a $7.50 target on May 10, 2024. Maxim Group, on August 16, 2023, reiterated a 'buy' rating with a higher target of $10.00.
Bottom Line
The recent insider buying activity in SCYX, alongside new positions from institutional investors, suggests growing interest in the company. Analyst ratings reinforce this sentiment, maintaining 'buy' recommendations with varied price targets. As always, remember that insider and institutional activities provide insights into market sentiment, but past actions do not predict future performance.
Related Filing Alerts
Source: Tinmouth Brian Philippe's Form 4 filing on $SCYX (Jun 26, 2026). Find the original filing: SCYX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts